Lung cancer screening: Utility of molecular applications in conjunction with low-dose computed tomography guidelines

Expert Review of Molecular Diagnostics

Volumn 16, Issue 4, 2016, Pages 435-447

  Palma, John F ^a   Das, Partha ^a   Liesenfeld, Oliver ^a  

^a ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

biomarkers; health economic evaluation; low dose computed tomography; Lung cancer; National Lung Screening Trial

Indexed keywords

ACETOIN; AUTOANTIBODY; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COMPLEMENT COMPONENT C9; CYTOKERATIN 19 FRAGMENT; ENDOGLIN; HAPTOGLOBIN; HAPTOGLOBIN BETA; K RAS PROTEIN; MELANOMA ANTIGEN 4; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; NEURON SPECIFIC ENOLASE; NY ESO 1 ANTIGEN; PEROXIREDOXIN 1; PLASMA KALLIKREIN; PROGASTRIN RELEASING PEPTIDE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; PROTEIN P16; PROTEIN P53; PROTEOME; SERUM AMYLOID A; SOMATOMEDIN BINDING PROTEIN 2; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTOME; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND;

BREATH ANALYSIS; BRONCHOSCOPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DNA METHYLATION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; EXPIRED AIR; FALSE POSITIVE RESULT; FAMILY HISTORY; GENE AMPLIFICATION; GENE MUTATION; GENE TRANSLOCATION; GENETIC SCREENING; GENOME ANALYSIS; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE POLICY; HEMOPTYSIS; HIGH RISK POPULATION; HUMAN; INDEL MUTATION; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; LUNG CANCER; LUNG CARCINOGENESIS; LUNG EMPHYSEMA; LUNG NODULE; MINIMALLY INVASIVE PROCEDURE; MOLECULAR DIAGNOSIS; MULTICENTER STUDY (TOPIC); PRACTICE GUIDELINE; PREDICTIVE VALUE; QUALITY OF LIFE; RADIATION DOSE; RADIATION EXPOSURE; RESPIRATORY EPITHELIUM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; THORAX RADIOGRAPHY; TRANSCRIPTOMICS; WEIGHT REDUCTION; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; EARLY CANCER DIAGNOSIS; ECONOMICS; LUNG NEOPLASMS; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC;

EID: 84958756066     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2016.1149469     Document Type: Review

References (80)

1. World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lung Cancer; 2012. [cited 2015 Jun 28]. Available from: http://globocan.iarc.fr/Pages/fact-sheets- cancer.aspx?cancer=lung
2. American Cancer Society. Cancer facts & figures - 2015; 2015. [cited 2015 Sep 03]. Available from: http://www.cancer.org/acs/groups/con tent/@editorial/documents/document/acspc-044552.pdf
3. U.S. National Institutes of Health. National cancer institute. SEER cancer statistics review (CSR) 1975-2012; 2015. [cited 2015 Sep 03]. Available from: http://seer.cancer.gov/csr/1975-2012/
4. Long F, Su JH, Liang B, et al. Identification of gene biomarkers for distinguishing small-cell lung cancer from non-small-cell lung cancer using a network-based approach. Biomed Res Int. 2015; 2015: 1-8.
5. Eurostat Press Office. 1 in 4 deaths caused by cancer in the EU28; 2014. [cited 2015 Sep 03]. Available from: http://ec.europa.eu/euro stat/documents/2995521/6131615/3-25112014-BP-EN/aab2c2d3- aed9-430a-a561-e188b8ef49d8
6. World Cancer Report. Edited by Bernard W. Stewart and Christopher P. Wild; 2014.
7. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd Ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (Suppl 5): e1S-29S.
8. Dhillon SS, Loewen G, Jayaprakash V, et al., Lung cancer screening update. J Carcinog. 2013; 12: 2.
9. U.S. National Institutes of Health. National cancer institute. cancer trends progress report. Financial burden of cancer care; 2014. [cited 2015 Sep 03]. Available from: http://progressreport.cancer.gov/after/economic-urden
10. U.S. Department of Health and Human Services. The health consequences of smoking-50 years of progress: a report of the surgeon general; 2014.[cited 2015 Sep 03]. Available from: http://www.cdc. gov/tobacco/data-statistics/sgr/50th-anniversary/index.htm
11. American Cancer Society. The global economic cost of cancer; 2010. [cited 2015 Sep 26]. Available from: http://www.cancer.org/acs/groups/content/@internationalaffairs/documents/document/acspc-026203.pdf
12. Park YS. Lung cancer screening: subsequent evidences of National Lung Screening Trial. Tuberc Respir Dis (Seoul). 2014; 77 (2): 55-59.
13. Pyenson BS, Sander MS, Jiang Y, et al. An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost. Health Aff (Millwood). 2012; 31 (4): 770-779.
14. Aberle DR, Adams AM, Berg CD, et al.; . The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365 (5): 395-409.
15. Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US preventive services task force recommendation. Ann Intern Med. 2013; 159 (6): 411-420.
16. Brothers JF, Hijazi K, Mascaux C, et al. Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med. 2013; 11 (1): 168.
17. De Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. preventive services task force. Ann Intern Med. 2014; 160 (5): 311-320.
18. American Lung Association. Providing guidance on lung cancer screening to patients and physicians. An Update from the American Lung Association Lung Cancer Screening Committee April 30; 2015.
19. Sozzi G, Boeri M. Potential biomarkers for lung cancer screening. Transl Lung Cancer Res. 2014; 3 (3): 139-148.
20. Transparency Market Research. Cancer diagnostics market (tumor biomarker tests, imaging, endoscopy and biopsy) - Global industry analysis, size, share, growth, trends and forecast, 2014 - 2020; 2014. [cited 2015 Oct 09]. Available from: http://www.transparencymarke tresearch.com/cancer-diagnostics-market.html
21. Detterbeck FC, Mazzone PJ, Naidich DP, et al. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5 Suppl): e78S-92S.
22. Recommendation Summary. U.S. preventive services task force; 2013.[cited 2015 Sep 03]. Available from: http://www.uspreventive servicestaskforce.org/Page/Topic/recommendation-summary/lungcancer- screening
23. Pinsky PF, Berg CD. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? J Med Screen. 2012; 19 (3): 154-156.
24. Centers for Disease Control and Prevention. Lung cancer screening guidelines and recommendations; 2015. [cited 2015 Sep 23]. Available from: http://www.cdc.gov/cancer/lung/pdf/guidelines.pdf
25. National Comprehensive Cancer Network. NCCN guidelines for patients. Lung cancer screening. Version 1.2015; 2015. [cited 2015 Sep 23]. Available from: http://www.nccn.org/patients/guidelines/lung-screening/index.html
26. Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013; 368 (8): 728-736.
27. McRonald FE, Yadegarfar G, Baldwin DR, et al. The UK Lung Screen (UKLS): demographic profile of first 88, 897 approaches provides recommendations for population screening. Cancer Prev Res (Phila). 2014; 7 (3): 362-371.
28. Maisonneuve P, Bagnardi V, Bellomi M, et al. Lung cancer risk prediction to select smokers for screening CT-a model based on the Italian COSMOS trial. Cancer Prev Res (Phila). 2011; 4 (11): 1778-1789.
29. Kovalchik SA, Tammemägi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung cancer death. N Engl J Med. 2013; 369 (3): 245-254.
30. Tammemägi MC, Church TR, Hocking WG, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014; 11 (12): e1001764.
31. Veronesi G, Maisonneuve P, Spaggiari L, et al. Diagnostic performance of low-dose computed tomography screening for lung cancer over five years. J Thorac Oncol. 2014; 9 (7): 935-939.
32. Yip R, Henschke CI, Yankelevitz DF, et al.; International Early Lung Cancer Investigators. The impact of the regimen of screening on lung cancer cure: a comparison of I-ELCAP and NLST. Eur J Cancer Prev. 2015; 24 (3): 201-208.
33. Patz EF Jr, Pinsky P, Gatsonis C, et al.; NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014; 174 (2): 269-274.
34. Horeweg N, Scholten ET, De Jong PA, et al. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. Lancet Oncol. 2014; 15 (12): 1342-1350.
35. Field JK, Van Klaveren R, Pedersen JH, et al. European randomized lung cancer screening trials: post NLST. J Surg Oncol. 2013; 108 (5): 280-286.
36. Field JK, Duffy SW, Baldwin DR, et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax. 2016; 71 (2): 161-170.
37. Infante M, Cavuto S, Lutman FR, et al.; Dante Study Group. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009; 180 (5): 445-453.
38. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012; 21 (3): 308-315.
39. Blanchon T, Bréchot J-M, Grenier PA, et al. Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer. 2007; 58 (1): 50-58.
40. Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with lowdose CT. Thorax. 2012; 67 (4): 296-301.
41. Yousaf-Khan U, Van Der Aalst C, De Jong P, et al. International association for the study of lung cancer. ORAL09.02 - results of the fourth screening round of the NELSON lung cancer screening study (ID 1354); 2015. [cited 2016 Jan 12]. Available from: http://library. iaslc.org/search?search-keyword=NELSON+
42. Kauczor HU, Bonomo L, Gaga M, et al.; European Society Of Radiology (ESR) and the European Respiratory Society (ERS). ESR/ERS white paper on lung cancer screening. Eur Respir J. 2015; 25 (9): 2519-2531.
43. Mukhopadhyay S. Utility of small biopsies for diagnosis of lung nodules: doing more with less. Mod Pathol. 2012; 25 (Suppl 1): S43-57.
44. Hassanein M, Callison J, Callaway-Lane C, et al. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res. 2012; 5 (8): 992-1006.
45. Masters GA, Krilov L, Bailey HH, et al. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015; 33 (7): 786-809.
46. Ha T-Y. MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw. 2011; 11 (3): 135-154.
47. Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol. 2014; 32 (8): 768-773.
48. Montani F, Marzi MJ, Dezi F, et al. miR-Test: a blood test for lung cancer early detection. J Natl Cancer Inst. 2015; 107 (6): djv063.
49. Hennessey PT, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One. 2012; 7 (2): e32307.
50. Shen J, Liao J, Guarnera MA, et al. Analysis of microRNAs in sputum to improve computed tomography for lung cancer diagnosis. J Thorac Oncol. 2014; 9 (1): 33-40.
51. Xing L, Su J, Guarnera MA, et al. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules. Clin Cancer Res. 2015; 21 (2): 484-489.
52. Warton K, Samimi G. Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci. 2015; 2: 13.
53. Begum S, Brait M, Dasgupta S, et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res. 2011; 17 (13): 4494-4503.
54. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000; 60 (21): 5954-5958.
55. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006; 66 (6): 3338-3344.
56. Hubers AJ, Prinsen CFM, Sozzi G, et al. Molecular sputum analysis for the diagnosis of lung cancer. Br J Cancer. 2013; 109 (3): 530-537.
57. Reszka E, Wasowicz W. Significance of genetic polymorphisms in glutathione S-transferase multigene family and lung cancer risk. Int J Occup Med Environ Health. 2001; 14 (2): 99-113.
58. Miura N, Nakamura H, Sato R, et al. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci. 2006; 97 (12): 1366-1373.
59. Fratta E, Coral S, Covre A, et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011; 5 (2): 164-182.
60. Gumireddy K, Li A, Chang DH, et al. AKAP4 is a circulating biomarker for non-small cell lung cancer. Oncotarget. 2015; 6 (19): 17637-17647.
61. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014; 4 (6): 650-661.
62. Elshimali YI, Khaddour H, Sarkissyan M, et al. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013; 14 (9): 18925-18958.
63. Ahn JM, Cho JY. Current serum lung cancer biomarkers. J Mol Biomark Diagn. 2013; S4: 001.
64. Li X-J, Hayward C, Fong P-Y, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med. 2013; 5 (207): 207ra142.
65. Xiang D, Garbett NC, Chaires JB, et al. Differential scanning calorimetry of blood plasma for lung cancer diagnosis. J Clin Oncol. 2010; 28 (15-suppl): e21085.
66. Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax. 2008; 63 (3): 228-233.
67. Chapman CJ, Healey GF, Murray A, et al. EarlyCDT®-lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012; 33 (5): 1319-1326.
68. Jett JR, Peek LJ, Fredericks L, et al. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer. 2014; 83 (1): 51-55.
69. Ajona D, Pajares MJ, Corrales L, et al. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst. 2013; 105 (18): 1385-1393.
70. Steiling K, Ryan J, Brody JS, et al. The field of tissue injury in the lung and airway. Cancer Prev Res (Phila). 2008; 1 (6): 396-403.
71. Silvestri G, Vachani A, Whitney D, et al; AEGIS Study Team. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med. 2015; 373 (3): 243-251.
72. Dent AG, Sutedja TG, Zimmerman PV. Exhaled breath analysis for lung cancer. J Thorac Dis. 2013; 5 (Suppl 5): S540-S550.
73. Mazzone PJ, Wang XF, Xu Y, et al. Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer. J Thorac Oncol. 2012; 7 (1): 137-142.
74. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014; 371 (19): 1793-1802.
75. Villanti AC, Jiang Y, Abrams DB, et al. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS One. 2013; 8 (8): e71379.
76. Mauchley D, Mitchell J. Current estimate of costs of lung cancer screening in the United States. Thorac Surg Clin. 2015; 25 (2): 205-215.
77. Mahadevia PJ, Fleisher LA, Frick KD, et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA. 2003; 289 (3): 313-322.
78. Pyenson BS, Henschke CI, Yankelevitz DF, et al. Offering lung cancer screening to high-risk medicare beneficiaries saves lives and is costeffective: an actuarial analysis. Am Health Drug Benefits. 2014; 7 (5): 272-282.
79. Shmueli A, Fraifeld S, Peretz T, et al. Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experience. Value Health. 2013; 16 (6): 922-931.
80. Cressman S, Lam S, Tammemagi MC, et al.; Pan-Canadian Early Detection of Lung Cancer Study Team. Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. J Thorac Oncol. 2014; 9 (10): 1449-1458.